162 related articles for article (PubMed ID: 35488886)
21. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
[TBL] [Abstract][Full Text] [Related]
22. IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.
Cheng HB; Yue W; Xie C; Zhang RY; Hu SS; Wang Z
Tumour Biol; 2013 Dec; 34(6):3555-9. PubMed ID: 23904262
[TBL] [Abstract][Full Text] [Related]
23. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
Paldor I; Drummond KJ; Kaye AH
J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
[TBL] [Abstract][Full Text] [Related]
24. Pro-inflammatory and proliferative microglia drive progression of glioblastoma.
Liu H; Sun Y; Zhang Q; Jin W; Gordon RE; Zhang Y; Wang J; Sun C; Wang ZJ; Qi X; Zhang J; Huang B; Gui Q; Yuan H; Chen L; Ma X; Fang C; Liu YQ; Yu X; Feng S
Cell Rep; 2021 Sep; 36(11):109718. PubMed ID: 34525361
[TBL] [Abstract][Full Text] [Related]
25. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
[TBL] [Abstract][Full Text] [Related]
26. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
[TBL] [Abstract][Full Text] [Related]
27. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
[TBL] [Abstract][Full Text] [Related]
28. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
Song X; Andrew Allen R; Terence Dunn S; Fung KM; Farmer P; Gandhi S; Ranjan T; Demopoulos A; Symons M; Schulder M; Li JY
Int J Clin Exp Pathol; 2011; 4(7):651-60. PubMed ID: 22076165
[TBL] [Abstract][Full Text] [Related]
29. Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.
Wang Z; Bao Z; Yan W; You G; Wang Y; Li X; Zhang W
J Exp Clin Cancer Res; 2013 Aug; 32(1):59. PubMed ID: 23988086
[TBL] [Abstract][Full Text] [Related]
30. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
32. Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration.
Kang S; Kwon HN; Kang S; Park S
Biochem Biophys Res Commun; 2020 Mar; 524(1):224-230. PubMed ID: 31983428
[TBL] [Abstract][Full Text] [Related]
33. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
Lasocki A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2018 Jan; 47():168-173. PubMed ID: 28988652
[TBL] [Abstract][Full Text] [Related]
34. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
35. Prediction of IDH1 Mutation Status in Glioblastoma Using Machine Learning Technique Based on Quantitative Radiomic Data.
Lee MH; Kim J; Kim ST; Shin HM; You HJ; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
World Neurosurg; 2019 May; 125():e688-e696. PubMed ID: 30735871
[TBL] [Abstract][Full Text] [Related]
36. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y
Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118
[TBL] [Abstract][Full Text] [Related]
37. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
[TBL] [Abstract][Full Text] [Related]
38. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
40. Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.
Ha SY; Kang SY; Do IG; Suh YL
J Neurooncol; 2013 May; 112(3):439-48. PubMed ID: 23412777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
